SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001104659-23-104803
Filing Date
2023-09-28
Accepted
2023-09-28 17:00:21
Documents
5
Group Members
BIOXCEL HOLDINGS, INC.VIMAL MEHTA

Document Format Files

Seq Description Document Type Size
1 SC 13D tm2327016d1_sc13d.htm SC 13D 92478
2 EXHIBIT 1 tm2327016d1_ex1.htm EX-1 5648
3 EXHIBIT 2 tm2327016d1_ex2.htm EX-2 120039
4 EXHIBIT 3 tm2327016d1_ex3.htm EX-3 110171
5 EXHIBIT 4 tm2327016d1_ex4.htm EX-4 81326
  Complete submission text file 0001104659-23-104803.txt   411335
Mailing Address 2614 BOSTON POST ROAD SUITE #33B GUILFORD CT 06437
Business Address 2614 BOSTON POST ROAD SUITE #33B GUILFORD CT 06437 203-643-8002
BioXcel LLC (Filed by) CIK: 0001651990 (see all company filings)

IRS No.: 202612128 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D
SIC: 7372 Services-Prepackaged Software

Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Subject) CIK: 0001720893 (see all company filings)

IRS No.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-90437 | Film No.: 231290638
SIC: 2834 Pharmaceutical Preparations